Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19

NCT05656443 is registered in ClinicalTrials.gov with Fujian Akeylink Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05656443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05656443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19
Lead sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 19, 2022
Completion date
July 14, 2023
Enrollment
1,246 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia